Upregulation of VEGF production by SPARC provides metastatic prostate cancer cells with a specific growth advantage in the bone microenvironment, thus blocking the interaction of SPARC with activated αv integrins should reduce bone metastasis [45]. The gene discussed is SPARC; the disease is Familial prostate cancer.